COVID-19 vaccine

BioNTech’s Q1 2025 revenue was €182.8 million, with a net loss of €415.8 million. The company is focusing on its oncology pipeline, including BNT327 and mRNA cancer immunotherapies. It’s also preparing for a variant-adapted COVID-19 vaccine for the 2025/2026 season and confirmed its full-year 2025 financial guidance.